BRPI1014994A2 - 2,4-diamino pirimidinas para o tratamento de doenças caracterizadas por proliferação excessiva ou anormal de células - Google Patents
2,4-diamino pirimidinas para o tratamento de doenças caracterizadas por proliferação excessiva ou anormal de célulasInfo
- Publication number
- BRPI1014994A2 BRPI1014994A2 BRPI1014994A BRPI1014994A BRPI1014994A2 BR PI1014994 A2 BRPI1014994 A2 BR PI1014994A2 BR PI1014994 A BRPI1014994 A BR PI1014994A BR PI1014994 A BRPI1014994 A BR PI1014994A BR PI1014994 A2 BRPI1014994 A2 BR PI1014994A2
- Authority
- BR
- Brazil
- Prior art keywords
- excessive
- treatment
- cell proliferation
- abnormal cell
- diseases characterized
- Prior art date
Links
- 230000002159 abnormal effect Effects 0.000 title 1
- 230000004663 cell proliferation Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical class NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09161496 | 2009-05-29 | ||
| EP10161628 | 2010-04-30 | ||
| PCT/EP2010/057408 WO2010136559A1 (en) | 2009-05-29 | 2010-05-28 | 2, 4 -diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1014994A2 true BRPI1014994A2 (pt) | 2016-05-03 |
Family
ID=42289495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1014994A BRPI1014994A2 (pt) | 2009-05-29 | 2010-05-28 | 2,4-diamino pirimidinas para o tratamento de doenças caracterizadas por proliferação excessiva ou anormal de células |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8410126B2 (pt) |
| EP (1) | EP2435411B1 (pt) |
| JP (1) | JP5756799B2 (pt) |
| KR (1) | KR20120135010A (pt) |
| CN (1) | CN102448943A (pt) |
| AP (1) | AP2011005978A0 (pt) |
| AR (1) | AR076620A1 (pt) |
| AU (1) | AU2010251943A1 (pt) |
| BR (1) | BRPI1014994A2 (pt) |
| CA (1) | CA2763700A1 (pt) |
| CL (1) | CL2011003022A1 (pt) |
| CO (1) | CO6470899A2 (pt) |
| EA (1) | EA201101674A1 (pt) |
| EC (1) | ECSP11011558A (pt) |
| IL (1) | IL216084A0 (pt) |
| MA (1) | MA33302B1 (pt) |
| MX (1) | MX2011012643A (pt) |
| PE (1) | PE20120370A1 (pt) |
| SG (1) | SG176599A1 (pt) |
| TW (1) | TW201107308A (pt) |
| UY (1) | UY32673A (pt) |
| WO (1) | WO2010136559A1 (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007257650A1 (en) * | 2006-06-15 | 2007-12-21 | Boehringer Ingelheim International Gmbh | 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase C-alpha |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| JP2011523646A (ja) | 2008-05-21 | 2011-08-18 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのリン誘導体 |
| US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
| DK2675794T3 (da) | 2011-02-17 | 2019-05-06 | Cancer Therapeutics Crc Pty Ltd | Selektive fak-inhibitorer |
| WO2012110773A1 (en) | 2011-02-17 | 2012-08-23 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
| AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| ES2940911T3 (es) * | 2016-06-27 | 2023-05-12 | Rigel Pharmaceuticals Inc | Compuestos de 2,4-diamino-pirimidina y su uso como inhibidores de IRAK4 |
| WO2019190259A1 (ko) * | 2018-03-30 | 2019-10-03 | 한미약품 주식회사 | 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 설폰아마이드 유도체 |
| HUE065486T2 (hu) | 2019-05-10 | 2024-05-28 | Deciphera Pharmaceuticals Llc | Fenilaminopirimidinamid autophágia inhibitorok és azok felhasználási eljárásai |
| HRP20231310T1 (hr) | 2019-05-10 | 2024-02-02 | Deciphera Pharmaceuticals, Llc | Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene |
| MX2021014218A (es) * | 2019-05-23 | 2022-01-06 | Corteva Agriscience Llc | Aril amidinas fungicidas. |
| ES3072710T3 (en) | 2019-06-17 | 2026-07-03 | Deciphera Pharmaceuticals Llc | Aminopyrimidine amide autophagy inhibitors and methods of use thereof |
| WO2022208454A1 (en) * | 2021-04-02 | 2022-10-06 | Bridge Biotherapeutics, Inc. | N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof |
| CN121358482A (zh) * | 2023-06-09 | 2026-01-16 | 艾斯特里昂株式会社 | 用于预防或治疗脑肿瘤的药物组合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1239485C (zh) * | 2000-05-22 | 2006-02-01 | 里奥制药有限公司 | 作为IL－1β和TNF－α抑制剂的二苯酮类 |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| JP4460292B2 (ja) | 2001-10-17 | 2010-05-12 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法 |
| ES2373226T3 (es) * | 2002-06-28 | 2012-02-01 | Astellas Pharma Inc. | Derivado de diaminopirimidincarboxamida. |
| SI1625121T1 (sl) * | 2002-12-20 | 2010-04-30 | Pfizer Prod Inc | Derivati pirimidina za zdravljenje abnormalne rasti celic |
| US7109337B2 (en) * | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| EA200601796A1 (ru) * | 2004-05-14 | 2007-04-27 | Пфайзер Продактс, Инк. | Пиримидиновые производные для лечения аномального клеточного роста |
| US20070032514A1 (en) * | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
| PE20080068A1 (es) | 2006-05-15 | 2008-03-17 | Boehringer Ingelheim Int | Compuestos derivados de pirimidina como inhibidores de la quinasa aurora |
| DK2089369T3 (da) * | 2006-10-19 | 2011-05-09 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme |
| KR20100132550A (ko) * | 2008-04-16 | 2010-12-17 | 포톨라 파마슈티컬스, 인코포레이티드 | ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드 |
| US8138339B2 (en) * | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
-
2010
- 2010-05-21 US US12/784,813 patent/US8410126B2/en active Active
- 2010-05-28 AP AP2011005978A patent/AP2011005978A0/xx unknown
- 2010-05-28 KR KR1020117031173A patent/KR20120135010A/ko not_active Withdrawn
- 2010-05-28 TW TW099117275A patent/TW201107308A/zh unknown
- 2010-05-28 EP EP10724385.9A patent/EP2435411B1/en active Active
- 2010-05-28 CN CN2010800234907A patent/CN102448943A/zh active Pending
- 2010-05-28 PE PE2011002012A patent/PE20120370A1/es not_active Application Discontinuation
- 2010-05-28 AR ARP100101883A patent/AR076620A1/es unknown
- 2010-05-28 EA EA201101674A patent/EA201101674A1/ru unknown
- 2010-05-28 AU AU2010251943A patent/AU2010251943A1/en not_active Abandoned
- 2010-05-28 MA MA34394A patent/MA33302B1/fr unknown
- 2010-05-28 UY UY0001032673A patent/UY32673A/es not_active Application Discontinuation
- 2010-05-28 CA CA2763700A patent/CA2763700A1/en not_active Abandoned
- 2010-05-28 MX MX2011012643A patent/MX2011012643A/es not_active Application Discontinuation
- 2010-05-28 BR BRPI1014994A patent/BRPI1014994A2/pt not_active Application Discontinuation
- 2010-05-28 SG SG2011086790A patent/SG176599A1/en unknown
- 2010-05-28 WO PCT/EP2010/057408 patent/WO2010136559A1/en not_active Ceased
- 2010-05-28 JP JP2012512388A patent/JP5756799B2/ja active Active
-
2011
- 2011-11-01 IL IL216084A patent/IL216084A0/en unknown
- 2011-11-29 CL CL2011003022A patent/CL2011003022A1/es unknown
- 2011-12-15 CO CO11173252A patent/CO6470899A2/es not_active Application Discontinuation
- 2011-12-27 EC EC2011011558A patent/ECSP11011558A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010251943A1 (en) | 2011-12-01 |
| US20110130401A1 (en) | 2011-06-02 |
| PE20120370A1 (es) | 2012-05-09 |
| TW201107308A (en) | 2011-03-01 |
| US8410126B2 (en) | 2013-04-02 |
| EP2435411A1 (en) | 2012-04-04 |
| UY32673A (es) | 2010-12-31 |
| ECSP11011558A (es) | 2012-01-31 |
| CL2011003022A1 (es) | 2012-07-13 |
| WO2010136559A1 (en) | 2010-12-02 |
| JP5756799B2 (ja) | 2015-07-29 |
| CO6470899A2 (es) | 2012-06-29 |
| CN102448943A (zh) | 2012-05-09 |
| CA2763700A1 (en) | 2010-12-02 |
| MA33302B1 (fr) | 2012-05-02 |
| SG176599A1 (en) | 2012-01-30 |
| IL216084A0 (en) | 2012-01-31 |
| JP2012528121A (ja) | 2012-11-12 |
| KR20120135010A (ko) | 2012-12-12 |
| AP2011005978A0 (en) | 2011-12-31 |
| MX2011012643A (es) | 2011-12-14 |
| AR076620A1 (es) | 2011-06-22 |
| EA201101674A1 (ru) | 2012-06-29 |
| EP2435411B1 (en) | 2014-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL216084A0 (en) | 2,4-diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation | |
| IL260117A (en) | Use of placental cells to treat diseases, syndromes or conditions of the lungs | |
| BRPI1015569A2 (pt) | compostos úteis para o tratamento de doenças degenerativas e inflamatórias. | |
| BR112013021366A2 (pt) | imidazo[5,1-f][1,2,4]triazinas para o tratamento de desordens neurológicas | |
| BRPI1013426A2 (pt) | organismos para produção de 1,3-butanodiol | |
| BR112012004377A2 (pt) | terapia de reposição enzimática com progressão de dose para tratamento de deficiência de esfingomielinase ácida. | |
| BRPI0807987A2 (pt) | Terapia de combinação para tratamento de distúrbios imunes. | |
| BR112013026313A8 (pt) | composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação anormal de fibroblastos e depósito de matriz extracelular | |
| BRPI0919920A2 (pt) | compostos para tratamento de doenças e desordens oftálmicas | |
| PL2504005T3 (pl) | Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby | |
| CO7071129A2 (es) | Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento | |
| CR11019A (es) | 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas | |
| BRPI1009783A2 (pt) | compostos para o tratamento de distúrbios metabólicos. | |
| BRPI0816784A2 (pt) | Fatores neuro-endócrinos para o tratamento de doenças degenerativas | |
| PT2514436T (pt) | Il-22 para utilização no tratamento de distúrbios microbianos | |
| BRPI0906618A2 (pt) | Derivados de diazepinorimidona de arilamida substituídos para o tratamento de doenças neu-rodegenerativas causadas por atividade anorma de gsk3-beta | |
| IL212814A0 (en) | Substituted pyrimidines for the treatment of diseases such as cancer | |
| GB2467710B (en) | Methods for treating social disorders | |
| BRPI1013618A2 (pt) | pirimidinas substituídas para o tratamento de câncer | |
| BRPI0811581A2 (pt) | Estimuladores de sgc, ativadores de sgc e combinações para o tratamento de distúrbios urológicos | |
| BRPI1007995A2 (pt) | orto-aminoamidas para o tratamento de cãncer. | |
| BRPI0911577A2 (pt) | derivados espiro-indol para o tratamento de doenças parasíticas. | |
| BR112012004836A2 (pt) | pirazinilpiridinas úteis para o tratamento de doenças proliferativas | |
| BRPI0822012A2 (pt) | Derivados de quinazolina de 6,7-dialcóxi úteis para o tratamento de distúrbios relacionados com câncer | |
| BRPI0818170A2 (pt) | 5-cianotienopiridinas para o tratamento de tumores. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |